How to buy Hoth Therapeutics stock

Hoth Therapeutics, Inc is a biotechnology business based in the US. Hoth Therapeutics shares (HOTH) are listed on the NASDAQ and all prices are listed in US Dollars. Hoth Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

Hoth Therapeutics share price

Use our graph to track the performance of HOTH stocks over time.

Hoth Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$1.40 - $4.15
50-day moving average	$1.89
200-day moving average	$1.96
Wall St. target price	$10.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.49

Buy Hoth Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Hoth Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Hoth Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Hoth Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-112.98%
Return on equity TTM	-204.44%
Profit margin	0%
Book value	$0.35
Market capitalisation	$34.1 million

TTM: trailing 12 months

Shorting Hoth Therapeutics shares

There are currently 896,082 Hoth Therapeutics shares held short by investors – that's known as Hoth Therapeutics's "short interest". This figure is 42.2% down from 1.5 million last month.

There are a few different ways that this level of interest in shorting Hoth Therapeutics shares can be evaluated.

Hoth Therapeutics's "short interest ratio" (SIR)

Hoth Therapeutics's "short interest ratio" (SIR) is the quantity of Hoth Therapeutics shares currently shorted divided by the average quantity of Hoth Therapeutics shares traded daily (recently around 5.0 million). Hoth Therapeutics's SIR currently stands at 0.18. In other words for every 100,000 Hoth Therapeutics shares traded daily on the market, roughly 180 shares are currently held short.

However Hoth Therapeutics's short interest can also be evaluated against the total number of Hoth Therapeutics shares, or, against the total number of tradable Hoth Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hoth Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Hoth Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0409% of the tradable shares (for every 100,000 tradable Hoth Therapeutics shares, roughly 41 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hoth Therapeutics.

Find out more about how you can short Hoth Therapeutics stock.

Hoth Therapeutics share dividends

We're not expecting Hoth Therapeutics to pay a dividend over the next 12 months.

Hoth Therapeutics share price volatility

Over the last 12 months, Hoth Therapeutics's shares have ranged in value from as little as $1.4 up to $4.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hoth Therapeutics's is 1.1559. This would suggest that Hoth Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Hoth Therapeutics overview

Hoth Therapeutics, Inc. , a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc. ; the North Carolina State University; Chelexa BioSciences, Inc. ; and the University of Cincinnati.

Frequently asked questions

• What percentage of Hoth Therapeutics is owned by insiders or institutions?

  Currently 27.539% of Hoth Therapeutics shares are held by insiders and 5.175% by institutions.

• How many people work for Hoth Therapeutics?

  Latest data suggests 3 work at Hoth Therapeutics.

• When does the fiscal year end for Hoth Therapeutics?

  Hoth Therapeutics's fiscal year ends in December.

• Where is Hoth Therapeutics based?

  Hoth Therapeutics's address is: 1 Rockefeller Plaza, New York, NY, United States, 10020

• What is Hoth Therapeutics's ISIN number?

  Hoth Therapeutics's international securities identification number is: US44148G1058

• What is Hoth Therapeutics's CUSIP number?

  Hoth Therapeutics's Committee on Uniform Securities Identification Procedures number is: 44148G105